| 13.88 0.3 (2.21%) | 03-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 16.88 | 1-year : | 19.72 |
| Resists | First : | 14.46 | Second : | 16.88 |
| Pivot price | 13.82 |
|||
| Supports | First : | 13.39 |
Second : | 12.73 |
| MAs | MA(5) : | 13.91  |
MA(20) : | 13.68 |
| MA(100) : | 18.36 |
MA(250) : | 22.73 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 55.9 |
D(3) : | 62.5 |
| RSI | RSI(14): 50.9 |
|||
| 52-week | High : | 35.34 | Low : | 12.11 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ JANX ] has closed below upper band by 44.1%. Bollinger Bands are 85% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 56 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 14.06 - 14.13 | 14.13 - 14.2 |
| Low: | 13.41 - 13.48 | 13.48 - 13.55 |
| Close: | 13.76 - 13.88 | 13.88 - 13.99 |
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Sun, 08 Mar 2026
Precision Trading with Janux Therapeutics Inc. (JANX) Risk Zones - Stock Traders Daily
Fri, 06 Mar 2026
Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV) and Janux Therapeutics Inc (JANX) - The Globe and Mail
Sun, 01 Mar 2026
Janux Therapeutics, Inc. (JANX) Commences Patient Dosing of JANX011 in Autoimmune Trial - Yahoo Finance
Sat, 28 Feb 2026
Janux Therapeutics JANX Net Loss Deepens To US$113.6 Million Challenging Bullish Growth Narratives - simplywall.st
Thu, 26 Feb 2026
Bristol Myers deal and wider 2025 loss at Janux Therapeutics (JANX) - Stock Titan
Thu, 26 Feb 2026
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 61 (M) |
| Held by Insiders | 4.168e+007 (%) |
| Held by Institutions | 6.9 (%) |
| Shares Short | 9,440 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.5564e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 576.6 % |
| Return on Equity (ttm) | -9.6 % |
| Qtrly Rev. Growth | 1e+007 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -3.99 |
| EBITDA (p.s.) | -4.02431e+007 |
| Qtrly Earnings Growth | -1.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -82 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -3.49 |
| Price to Cash Flow | 2.52 |
| Dividend | 0 |
| Forward Dividend | 1.014e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|